SCHEMBL4135317

SCHEMBL4135317

O=C(Nc1ccc(Cl)cc1)c1ccsc1NC(=O)C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 2/20 0.53
POLB P06746 2/20 0.49
LMNA P02545 4/20 0.47
HTT P42858 1/20 0.47
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
P2RX1 P51575 2/20 0.44
MAPK8 P45983 1/20 0.44
P2RX4 Q99571 1/20 0.44
P2RX7 Q99572 1/20 0.44
TMPRSS4 Q9NRS4 1/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147437 0.83 POLB (0.49) ANO1POLBLMNARAB9ANPC1
SCHEMBL28310266 0.78 LMNA (0.49) POLBLMNAHTTHDAC8P2RX1
SCHEMBL5550330 0.77 HDAC1 (0.67) ANO1LMNAHDAC1HDAC7HDAC8
SCHEMBL4147912 0.77 P2RX1 (0.56) HTTP2RX1MAPK8P2RX4P2RX7
SCHEMBL21577823 0.76 MAPT (0.51) POLBLMNAHTTP2RX1MAPK8
SCHEMBL4141410 0.76 PTPN2 (0.62) MAPK8KDM4EKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4147196 0.75 ANO1 (0.53) ANO1LMNAHTTPDK1PDK2
SCHEMBL5478399 0.75 PTK2 (0.63) HTTMAPK8RAB9ANPC1MAPT
SCHEMBL4132599 0.75 RXFP1 (0.56) HTTRAB9ANPC1KDM4EKMT2A
SCHEMBL7531362 0.72 KMT2A (0.62) MAPTKDM4EKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US claimed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP claimed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-06-04 US disclosed
EP-1802634-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-07-04 EP disclosed
WO-2006044826-A2 THIOPHENS AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143411-A1 Thiophens and Their Use as Anti-Tumor Agents TP53, BRDT, VHL ANO1 3854/4885POLB 2342/4885LMNA 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.